In this thesis tumor scintigraphy by means of new radiophannaceuticals is described, based on the binding of a peptide hormone, soomatostatin, to its receptors, which are often present in large numbers on various endocrine tumors. Consequently, these tumors can be visualized by gamma camera scintigraphy after in vivo administration of radiolabeled somatostatin analogues which have similar high affinities for the somatostatin receptor. Before discussing this in more detail, brief introductions are given about radioactivity, radiophannaceuticals, somatostatin and somatostatin receptor-positive tumors. The first section of tltis chapter briefly describes the history of radionuclides from the time of discovery of radioactivity via the general availability of artificial radionuclides to the first tumor-seeking applications of radionuclides. In the second section the general biochemical principles of scintigraphic imaging are presented by a description of the three different types of current radiophannaceuticals, according to their structure and biochentical behaviour, while special attention is paid to the developments in the field of tumor scintigraphy. More specifically, this chapter will be concluded with a section about sonuaostaiin and tumors containing receptors for somatostatin. This final section is intended as an introduction to the following chapters dealing with the preparation, the in vitro validation, the kinetic handling by the isolated perfused rat liver, and the in vivo application in rats and humans, of two radiolabeled somatostatin analogues for the scintigraphic imaging of sonuaostarin receptor-containing tumors.

, , , ,
The co-operation in this project with Mallinckrodt Medical B. V. is gratefully acknowledged
E.P. Krenning (Eric)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Bakker, W. (1992, May 20). Radiopharmaceuticals for scintigraphy of somatostatin receptor-positive tumors. Retrieved from